<DOC>
	<DOC>NCT01250158</DOC>
	<brief_summary>The purpose of this study is to determine whether the PILP-kit can be safely used, within specific performance parameters, to isolate and perfuse the liver with a chemotherapeutic drug for the treatment of patients with unresectable liver metastases.</brief_summary>
	<brief_title>Liver-PILP First-in-Man</brief_title>
	<detailed_description>The objective of this Medical Device Study, is to demonstrate the feasibility of the liver PILP intervention. The liver PILP intervention will be considered feasible if the procedure is demonstrated to be safe and the liver PILP kit performs according to specifications.</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Liver Extracts</mesh_term>
	<criteria>1. Subjects with ECOG (Eastern Cooperative Oncology Group) stages 0 or 1 2. Unresectable metastatic disease predominant in the liver 1. More than 60 % tumor involved liver tissue 2. Abnormal vascular anatomy 3. Severe atherosclerosis 4. Dissection and/or thrombotic occlusion and/or aneurysm of the aorta, iliac or hepatic arteries 5. Short suprahepatic vena cava segment (&lt; 1.5 cm) 6. One or both jugular veins are occluded 7. Other severe, concomitant diseases regarding the subject status</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Liver Percutaneous Isolated Localized Perfusion</keyword>
	<keyword>PILP</keyword>
	<keyword>Isolated Hepatic Perfusion</keyword>
	<keyword>IHP</keyword>
	<keyword>Liver metastases</keyword>
	<keyword>Unresectable liver metastases of different etiologies</keyword>
</DOC>